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Abstract
Background: The prevalence of methamphetamine use disorder (MUD) in the United States has risen dramatically
in the past four decades and is concentrated in populations such as men who have sex with men (MSM). Despite
the public health consequences of MUD, there are no FDA-approved psychopharmacological treatments.
Psychosocial treatment alone has been shown to reduce methamphetamine use, but high attrition rates limit
treatment efficacy. Promising findings from animal models of MUD using exogenous oxytocin, a social
neuropeptide, have set the stage for translational work. Along with unique anti-addiction effects, oxytocin holds a
primary role in enhancing social salience and modulating stress. In humans, oxytocin administration, combined with
evidence-based psychosocial interventions, may act synergistically to improve addiction treatment outcomes and
improve retention rates in current MUD treatment.
Methods/design: We are conducting a randomized, double-blind, placebo-controlled trial of oxytocin-enhanced
motivational interviewing group therapy (MIGT). Oxytocin or placebo 40 IU is administered intranasally in
conjunction with six, weekly MIGT sessions. We will recruit 50 MSM, initiating treatment for MUD from specialized
community health programs in San Francisco, CA, USA. Individuals will be randomized (1:1) to receive six, weekly
sessions of MIGT with or without oxytocin. Our primary outcome is session attendance. Other outcomes of interest
include: measures of group cohesion, anxiety, psychophysiology, and stimulant craving and use.
Discussion: This will be the first study of oxytocin’s effects in humans with MUD. Findings from this novel protocol
will attempt to bridge existing animal data with the need for innovative clinical treatments for MUD, inform the
growing field of pharmacologically-enhanced psychotherapy, and help to elucidate mechanisms behind oxytocin’s
potential anti-addiction effects.
Trial registration: ClinicalTrials.gov, ID: NCT02881177. Registered on 26 August 2016.
Keywords: Methamphetamine use disorder, Meth, Stimulant, Oxytocin, Men who have sex with men, Motivational
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Background
Methamphetamine is a potent psychostimulant with
high abuse potential [1]. Methamphetamine and
amphetamine-type stimulants are second only to canna-
bis as the most frequently used illicit substance world-
wide [2], and, according to the 2017 Global Drug Survey
[3], methamphetamine was the illicit substance most
likely to lead to emergency medical treatment seeking.
High healthcare utilization contributes to the multifac-
torial economic burden of methamphetamine, which is
estimated to be upwards of US$23.4 billion in the United
States (US) alone (Rand Corporation, 2008). The preva-
lence of methamphetamine use disorder (MUD) in the
US has risen dramatically in the past four decades, with
high concentrations among men who have sex with men
(MSM) [4–6]. Despite the personal and societal conse-
quences of methamphetamine use, no pharmacological
agent currently has an FDA-designated indication to
treat MUD [7, 8].
Psychosocial treatment alone has been shown to re-
duce methamphetamine use and rates of relapse, with a
longer duration of treatment producing better results
[9–13]. However, methamphetamine users exhibit high
attrition rates of 60% or more, which limits the effective-
ness of treatment and leads to missing data and validity
issues in clinical research contexts [14]. This complicates
efforts to identify pharmacotherapy candidates or to im-
prove evidence-based psychosocial treatments for MUD
[8, 15]. Methamphetamine is associated with impairments
in social cognition and theory of mind, including a hyper-
sensitivity to social threat, which likely contribute to re-
duced treatment adherence and retention [16–19]. Social
rehabilitation, often in the form of group and family
therapy, is a prominent component of gold-standard
psychosocial treatments for MUD [20, 21]. Even in animal
models of methamphetamine addiction, socially housed—
versus individually housed—rats were protected against
escalating methamphetamine self-administration [22].
Given the social complexities and challenges surrounding
MUD clinical treatment and research, an adjunctive
pharmacotherapy that might enhance social cognition and
boost engagement and retention in effective psychosocial
treatment could greatly improve outcomes [23].
Oxytocin, a hypothalamic peptide that plays a critical
role in mammalian attachment and affiliative behavior
[24–26], administered exogenously, is a promising candi-
date as an adjunctive addiction treatment [27, 28]. Oxy-
tocin has unique anti-addiction effects [27, 29] along
with social salience [30] and stress-tempering properties
[31–33], which together may shift attentional bias to-
ward positive social reward at the expense of condi-
tioned drug-related reward [28, 34]. Oxytocin is a large,
hydrophilic molecule, so does not readily cross the
blood-brain barrier after peripheral administration. The
intranasal route is thus far the most efficient way to
deliver oxytocin to the human central nervous system
[35, 36] and is extremely safe and tolerable [37]. What is
more, there are no discernable subjective effects (i.e., re-
search participants cannot typically guess whether they
have received oxytocin versus placebo), which allows the
use of an inactive placebo [37].
Methamphetamine self-administration in rats has been
shown to dysregulate the oxytocin system [38–40], and
some evidence for this exists in humans [41]. In animal
models of methamphetamine addiction, oxytocin adminis-
tration reduces the acquisition and increases extinction of
compulsive methamphetamine self-administration and re-
duces stress-primed and drug-primed reinstatement of
methamphetamine-seeking behavior [27, 42–47]. In
addition, oxytocin administration attenuates metham-
phetamine tolerance and withdrawal, methamphetamine-
induced stereotyped movements, methamphetamine-in-
duced conditioned place preference, and reduces
methamphetamine-induced c-Fos expression in areas of
the basal ganglia implicated in addiction [44, 48–51]. In
humans, oxytocin has demonstrated some efficacy in
early trials with alcohol, cannabis, opioid, and cocaine
users [52, 53]. To our knowledge, this will be the first
study to investigate the effects of intranasally administered
oxytocin on the symptoms of MUD in humans.
Oxytocin administration in combination with evidence-
based group psychotherapy—oxytocin-enhanced motivat
ional interviewing group therapy (OE-MIGT)—may syn-
ergistically enhance treatment outcomes and address the
notoriously high drop-out rates evident in MUD popula-
tions. We aim to investigate the effectiveness of intrana-
sally administered oxytocin on MIGT treatment
engagement. Specifically, we hypothesize that oxytocin
will increase attendance at treatment sessions. In addition,
we will estimate effect sizes and assess procedures used to
test oxytocin’s effects on group cohesion, anxiety, psycho-
physiological stress reactivity, and stimulant craving and
use for future trials. This novel translational protocol at-
tempts to bridge ample animal data with the need for in-
novative clinical treatments for MUD.
Methods/design
Study design
This is a randomized, double-blind, placebo-controlled
study of OE-MIGT. Specifically, intranasally administered
oxytocin or placebo will be administered in conjunction
with each of six, weekly, 90-min MIGT sessions.
Motivational interviewing group therapy (MIGT)
Motivational interviewing (MI) is defined as a “collab-
orative conversation style for strengthening a person’s
own motivation and commitment to change” a behavior
[54], be it increasing engagement in treatment or
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discontinuing or cutting down methamphetamine use.
MI is client-centered; as a result, the client generates
any and all treatment goals and the personalized plans
for attaining them. When conducting MI in group set-
tings, co-facilitators use MI-consistent techniques
(open-ended questions, affirmations, reflections, and
summarization) in the context of the spirit of MI (one of
collaboration, compassion, acceptance, and evocation) in
order to foster healthy interactions among members and
co-facilitators that are focused on exploring healthy
behavior change. MIGT co-facilitators aim to guide
members through four general group phases: (1) Engage-
ment – enlist members to “open up” by involving them in
meaningful relationships based in understanding and ac-
ceptance, (2) Exploring Perspectives – collaboratively, and
strategically, narrow the focus from cohesion-building to
members’ perspectives about their current situations, (3)
Broadening Perspectives – elicit perspectives and ideas
about change, motivation to change, and hopes for suc-
cess, and (4) Moving Into Action – develop specific plans
for how to implement change [55]. In this way, MIGT
can improve personal recognition of ambivalence,
support autonomy, increase motivation and commit-
ment to change, and improve treatment engagement
and participation [55].
The MIGT cohorts in this study will consist of two
co-facilitators, one will be a licensed psychiatrist and the
other will be a mental health trainee (PhD, PsyD, or
psychiatry resident) along with four to six group mem-
bers. All MIGT sessions will be conducted at the
Alliance Health Project in San Francisco, CA, USA. A
semi-structured, closed-admission, time-limited (six ses-
sions) OE-MIGT manual for methamphetamine users
was developed for this study using guidance from
Wagner and Ingersoll (2013) [55]. Included are four
brief psychoeducational components for optional use
during the first four sessions: stages of change, ambiva-
lence and a decisional balance chart for methampheta-
mine use, attachment theory and social support, and
managing stress. These topics aid in the Engagement
and Exploring Perspectives phases of the group, are de-
signed to maximize the effects of intranasally adminis-
tered oxytocin on MIGT for MUD, and correspond to
the specific objectives of this research study. The final
two sessions are left unstructured in order to allow more
time for Broadening Perspectives and Moving Into Ac-
tion. Adherence raters will assess session transcripts
using motivational interviewing treatment integrity
(MITI) 4.2; a coding system designed to measure group
facilitators’ adherence to MI [56]. Consistent with previ-
ous work by the research team, a fidelity checklist
reflecting the content of the session will be developed in
order to determine whether the intervention was deliv-
ered as intended. Prior to participant enrollment,
facilitators will receive training from an MI expert to en-
sure competency [57, 58].
Power analysis
A sample size of 25 per treatment condition will provide
us with > 99% power to detect an effect size comparable
to the large between-condition effect size (d = 1.44) ob-
served for attendance from our preliminary 3-week trial
in cocaine users [53] with a two-tailed alpha = 0.05. In
addition, this sample size will provide 80% power to de-
tect an effect size of 0.81 or greater.
Setting and study population
Previous evidence suggests that oxytocin administration
may lead to different outcomes based on the gender [59]
and sexual orientation [60] of recipients. To control for
this, we limited study participation to men who have sex
with men (MSM). Fifty MSM who meet the criteria for
MUD will be enrolled in the current study. Participants
will be recruited from community mental health pro-
grams specializing in this clinical population in San
Francisco, CA, USA, including the San Francisco AIDS
Foundation, the Alliance Health Project, the Positive
Health Program HIV/AIDS Clinic, as well as from study
flyers posted in the community. Due to the specificity of
our patient population, we acknowledge that participants
may recognize each other or even belong to the same
social circles. While we do not formally measure
pre-existing relationships among those assigned to the
same therapy cohort, we do take steps to ensure that in-
timate partners are not assigned to the same therapy co-
hort by collecting names of intimate partners as well as
any community member that each potential participant
would not want to be enrolled with in group therapy.
Inclusion and exclusion criteria
The inclusion criteria are: (1) 18 to 65 years old, (2)
male-identified, (3) history of sexual contact with men,
(4) meet Diagnostic and Statistical Manual of Mental
Disorders, fifth edition (DSM-5) criteria for severe MUD,
and (6) considering initiating treatment for MUD or ini-
tiated treatment within the past month. Excluded from
this study are individuals with: (1) a diagnosis of bipolar
I disorder, (2) evidence of opioid use within the past
month, (3) severe alcohol use disorder with withdrawal
symptoms, (4) suicidal ideation with intent or plan or
homicidal ideation within the past 90 days, (5) suicide
attempt in the past 6 months, (6) cognitive impairment
or behavioral issues precluding participation in group
therapy, (7) diseases likely to influence hormonal or neu-
roendocrine status or taking hormone supplements, (8)
conditions preventing nasal spray administration (e.g.,
nasal obstruction or frequent nose bleeds), and (7)
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allergies to E216, E218, or chlorobutanol hemihydrate
(preservatives in nasal spray).
Identification of target sample (eligibility screen)
Interested individuals will undergo initial screening for
eligibility using a brief, structured telephone interview.
To determine full eligibility, participants will attend an
initial in-person assessment where informed written
consent will be obtained by study staff prior to any study
procedures. See Fig. 1 for study flow diagram. Sociode-
mographic variables will be collected by a clinical asses-
sor, including: age, gender identification, sexual
orientation using the Kinsey Scale [61], race, education,
employment status, annual income, living situation, rela-
tionship status, HIV status, medical history, and medica-
tions. The subsections of Major Depressive Disorder,
Manic Episodes, Alcohol Use Disorder, Substance Use
Disorders, and Psychotic Disorders of The Mini Inter-
national Neuropsychiatric Interview (MINI) 7.0.0 [62]
and the Suicide subsection from the Structured Clinical
Interview for DSM-5 (SCID-5) [63] will be administered.
Participants will provide a urine sample and undergo
additional clinical interviews and self-assessment ques-
tionnaires at this initial visit. A study clinician will per-
form a brief medical examination, including examination
of the nasal mucosa.
Procedure
Eligible individuals enrolled in the study will be random-
ized, using a computer-generated random number se-
quence, to receive MIGT along with either oxytocin or
placebo administration prior to each session. Each mem-
ber of a specific MIGT cohort will receive the same
study drug as the other members of that cohort, and
members of each MIGT cohort will receive the same
study drug for all six sessions. Blinding procedures will
be controlled by Wellspring Compounding Pharmacy
(Berkeley, CA, USA).
Previous work has shown that intranasal oxytocin ad-
ministration begins to have physiological effects within
30 min and lasts for at least 90 min [35]. Thirty minutes
prior to beginning each MIGT session, the study
physician will administer the study drug (Wellspring
Compounding Pharmacy, Berkeley, CA, USA) intrana-
sally using a mucosal atomization device (MAD300; Tel-
eflex technologies, Mooresville, NC, USA) attached to a
1-mL Luer-lock syringe. The oxytocin will be prepared
as 40 International Units (IU) of oxytocin per 1mL. Par-
ticipants will receive 1 mL total, with 0.5 mL adminis-
tered in each nostril using two separate syringes (with
0.06 mL additional drug in the first syringe to account
for the MAD300 dead space). The administration proce-
dures are consistent with recommendations for stan-
dardized intranasal drug administration [64]. Study drug
administration will occur with all members present in the
group therapy space, and the order of administration to
individuals within a cohort will be randomized at each
session.
To test tolerability to the study drug, participants will
complete an Oxytocin Side Effect Checklist (OTSE), a list
of 21 possible side effects [37] and the opportunity to re-
port any other adverse effects, after each MIGT session. In
addition, participants will be asked after each session to
guess whether they have received oxytocin or placebo.
Substance use data collection
A urine sample will be collected at each study visit. A
point-of-care, Clinical Laboratory Improvement Amend-
ments (CLIA)-waived, 10-panel, Toxicology iCup Dx
drug screen (Alere Inc., Waltham, MA, USA) will be
used to screen samples for methamphetamine and other
common substances of abuse.
Audiovisual data collection
Audio and video of each 90-min MIGT session will be
recorded. The audio recording will be captured using
the Blue Yeti USB omnidirectional microphone (Blue-
mic, Westlake Village, CA, USA) and recorded using
Audacity audio software (Version 2.1.3, 2017) at a sam-
ple rate of 48,000 Hz. Each co-facilitator and group
member will be video recorded individually using a Goo-
gle Nexus 7 Tablet (Google, Menlo Park, CA, USA)
equipped with a 5.0-MP camera and recorded at a
1280 × 720 resolution and 30 frames per second.
Fig. 1 Study flow diagram
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Psychophysiology data collection
Participants and co-facilitators will each be equipped
with a Zephyr™ BioHarness v3.0 (Zephyr Technology,
Auckland, New Zealand), wearable, wireless, psycho-
physiology data collection equipment. Once a clear
signal is established, participants will be comfortable
seated for a silent, 5-min baseline physiology recording.
The Zephyr™ TEAM System using OmniSense Software
(Version 4.2.4) will record a continuous electrocardio-
gram (sampled at 250 Hz), respiratory rate, temperature,
and three-axis accelerometry to measure posture and ac-
tivity level throughout each 90-min MIGT session.
Psychophysiology data will be pre-processed using
MindWare HRV software (v3.1.2, MindWare Technolo-
gies, Ltd., Gahanna, OH, USA). Artifacts will be identi-
fied via MindWare’s dual MAD/MED and IBI Min/Max
artifact detection algorithms derived from established
strategy [65] and then processed manually. High-fre-
quency heart rate variability (HF-HRV) is used as an in-
dicator of parasympathetic nervous system activity and a
primary psychophysiological variable of interest with re-
gard to human social behavior. HRV is reduced in meth-
amphetamine users when compared to matched healthy
controls [66], and oxytocin has been previously shown
to increase HRV via variable changes of increased
HF-HRV and decreased Detrended Fluctuation Analysis
(DFA-1), which measures how “self-similar” the data are
[67]. Evidence suggests that autonomic cardiac control
may moderate the relationship between oxytocin and so-
cial behavior, and HRV may play a key role in psychiatric
patient response in treatment trials of oxytocin [68].
Self-assessment measures
Participants will complete self-assessment measures on
Google Nexus 7 Tablets via Research Electronic Data Cap-
ture (REDCap), an online data capture tool, hosted by the
University of California, San Francisco. At the initial visit,
participants will be asked their preferred term for meth-
amphetamine, and all future references to the drug in
self-assessment questionnaires will use the individual re-
spondent’s preferred term. The timing of administration
of self-assessment measures is shown in Fig. 2.
1. Social and group cohesion measures
1.1 The Group Questionnaire (GQ) [69], a 30-item
measure of the quality of the therapeutic rela-
tionships in a group setting
1.2 The Social Provisions Scale (SPS) [70], a 24-item
measure of the degree to which respondents’
social relationships provide various dimensions of
support
1.3 The Inclusion of Others in the Self (IOS) [71], a
measure assessing perceived interpersonal
connectedness to various “others” for which
respondents choose one in a series of images of
increasingly overlapping circles. The current
study measures participants’ relationships with:
methamphetamine, methamphetamine-using
communities, the LBGTQ community, their
most intimate relationship, and their family of
origin. The final administration of this question-
naire also asks about their relationship with
their MIGT cohort for the study
1.4 The Sexual Risk-Taking Behavior (SRTB) ques-
tionnaire [9, 72] will be used to conduct a struc-
tured interview to assess risky sexual behaviors
over the past 6 weeks. This measure asks the
same questions regarding sex while sober and
sex while under the influence of
methamphetamine
2. Stress reactivity measures
2.1 The Six-Item State-Trait Anxiety Inventory Short
Form (STAI-6) [73], a validated measure of the
three highest anxiety-present and three highest
anxiety-absent items from the state portion of the
full State-Trait Anxiety Inventory [74]
3. Substance use measures
3.1 The Methamphetamine Craving Questionnaire-
Brief (MCQ-Br), adapted from the Stimulant
Craving Questionnaire-Brief [75], a 10-item
measure of methamphetamine craving using a
7-point Likert scale
3.2 Self-reported methamphetamine use as
measured by a Timeline Follow Back (TLFB),
self-administered in our protocol [76], an assess-
ment of daily use estimates for alcohol and
other substances over the past 7 days [77]
3.3 The Readiness to Change Questionnaire
(RTCQ) [78], adapted for methamphetamine
users, is a 12-item measure based on the stages-
of-change model [79]
Psychometric variables, including sociodemographic
and diagnostic measures described above, that are pertin-
ent to the unique combination of MUD, MIGT, and oxy-
tocin administration, will be collected during the initial
screening visit. Additional variables will include the fol-
lowing: The Experiences in Close Relationship Scale –
Short Form (ECR-S) [80], which is a 12-item measure of
the construct of adult attachment, resulting in scores for
attachment anxiety and attachment avoidance. For this
study, we will substitute the term “romantic” for “intim-
ate,” which we defined as “emotional closeness, including
close family relationships and/or romantic relationships.”
The Adverse Childhood Experiences (ACE) Questionnaire
[81] is a 10-item measure of childhood experiences of
abuse and neglect. ACE scores have a strong graded rela-
tionship to the risk of developing and maintaining
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substance use disorders [82] and modify the relationship
between intranasally administered oxytocin and cortisol
reactivity in stimulant users [31]. The State-Trait Anxiety
Inventory (STAI) [74] is a 40-item measure; 20 items as-
sess for state anxiety and 20 items assess for trait anxiety.
Lastly, subsections of the Addiction Severity Index-Lite
(ASI-Lite) [83] will be used to assess quantity of substance
use in the past 30 days as well as lifetime use patterns.
Data management
All electronic data will be stored on encrypted hard
drives or password-protected computers. Hard copies of
any data will be kept in locked filing cabinets in a secure
office. All questionnaire data will be de-identified. An in-
dependent data monitoring committee (DMC) will re-
view accumulated data on a regular basis. Additionally,
the study’s Institutional Review Board (IRB) will monitor
the trial and conduct an audit once per year.
Data Analysis Plan
Descriptive statistics will be used for demographic infor-
mation and other baseline characteristics. Our dichotom-
ous primary outcome measure (in attendance/absent) will
be compared between oxytocin and placebo treatment
conditions using generalized estimating equations to ac-
commodate for correlations among the observations
Fig. 2 Eligibility and assessment timetable
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originating from the same participant and correct for
interdependence resulting from MIGT cohort member-
ship. Secondary outcomes collected at each MIGT session
consist of group cohesion as measured by the GQ,
self-reported anxiety as measured by the STAI-6, psycho-
physiological measures (including heart rate, HF-HRV,
and temperature), methamphetamine craving as measured
by the MCQ-Br, and urine drug screen. Given the explora-
tory nature of this novel study design, we will use descrip-
tive statistics and estimate Cohen’s d effect sizes for
secondary outcomes. Effect sizes will be calculated by sub-
tracting the mean change in the oxytocin group from the
mean change in the placebo group and dividing by the
pooled baseline standard deviation. If there is substantial
missing data, we also will consider using mixed linear
models or multiple-imputation techniques to estimate
mean change values in each treatment group with greater
accuracy. Additional exploratory outcome measures col-
lected at two timepoints, baseline and after the final
MIGT session, consist of the SRTB, SPS, IOS, and RTCQ
and will be processed using the same methodology. Re-
sults of secondary outcomes will be considered explora-
tory, and further confirmatory studies would be needed to
confirm the results. ECR-S, ACE, STAI, and subsections
of the ASI-Lite, along with baseline measurements of the
SPS, IOS, SRTB, and RTCQ, will be explored as potential
predictors of oxytocin response using Pearson’s correl-
ation coefficients.
In addition to utilizing psychophysiology measures re-
corded during MIGT sessions as a secondary outcome
variable in our main data analysis approach, we will
utilize models designed to explore physiological syn-
chrony, contagion, and other aspects of shared physio-
logical states [84].
Discussion
The high prevalence of MUD among MSM leads to signifi-
cant health disparities, including increased risk for HIV
seroconversion. Currently, no psychopharmacological agent
is FDA-approved for the treatment of MUD. This investiga-
tion represents the first randomized clinical trial to admin-
ister the social peptide, oxytocin, to individuals with MUD.
Data from this study should inform further development
of oxytocin’s role in psychopharmacological-psychosocial
combination treatment. Outcomes aim to further elucidate
the potential mechanisms of OE-MIGT for MUD. Overall,
this study aims to address methamphetamine use, treat-
ment engagement, and stress reactivity in a difficult-to-treat
population for whom current attrition rates are high
(Additional file 1).
Limitations and future directions
The current study will only include men who identify
as having sex with men; therefore, results may not
generalize to other genders and sexual orientations.
There may be further selection bias regarding the mo-
tivation and engagement of participants who choose to
take part in our study protocol. Furthermore, studies
with substance use disorder populations often must
deal with missing data from attrition. Our self-report
measures increase the risk of reporting bias, although
objective measures of psychophysiology will also be ex-
amined. Lastly, group therapy studies present inherent
complications regarding statistical analyses. We will
take these factors into account, although likely at the
expense of statistical power. Despite these limitations,
this study has many novel features and effect sizes will
contribute to ongoing research. Future goals involve
the further development of oxytocin-enhanced psycho-
therapy and expanding this treatment modality to other
patient populations.
Trial status
Protocol version 1.0. Recruitment started on 27 March
2017 and is estimated to end around 31 December 2018.
Additional file
Additional file 1: Standard Protocol Items: Recommendations for
Interventional Trials (SPIRIT) 2013 Checklist: recommended items to
address in a clinical trial protocol and related documents*. (DOC 121 kb)
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